SARS-CoV-2 IgG Antibody and its Clinical Correlates in Convalescent Plasma Donors: An Indian Experience
Tóm tắt
SARS-CoV-2, a novel coronavirus, emerged a year ago in Wuhan, China causing a new pandemic. Convalescent plasma therapy has been applied previously to many infectious diseases and has shown a successful result. This study was planned to assess the Anti-SARS-CoV-2 IgG antibody levels in convalescent COVID-19 patients. In this study, serum samples from 210 persons infected by SARS-CoV-2, treated and discharged from the hospital were collected. Anti-SARS-CoV-2 IgG antibody levels were detected using a chemiluminescence assay. A directory of convalescent plasma donors was created. Anti-SARS-CoV-2 IgG antibody levels vary substantially in the study population with a mean of 51.2 AU/ml. On comparing the serum anti-SARS-CoV-2 IgG antibody levels, a significant difference was observed between the subjects who had cough and those who did not (p = 0.0004). Similar significant findings were found with total protein and globulin levels on comparing the individuals with different antibody status (positive, negative and equivocal). The middle-aged and old age people had high Ab titres compared to younger individuals and the duration of the hospital stay was found to be positively correlated with the anti-SARS-CoV-2 IgG antibody. Cough, age and duration of the hospital stay was found to play a significant role in the development of Anti-SARS-CoV-2 IgG levels. Further, the data suggests that blood groups have a lesser impact on the severity of disease and the development of antibodies. Patients who present with the cough are more likely to develop antibodies.
Tài liệu tham khảo
Coronavirus Update (Live): 81,144,994 Cases and 1,771,981 Deaths from COVID-19 Virus Pandemic - Worldometer [Internet]. [cited 2020 Dec 28]. Available from: https://www.worldometers.info/coronavirus/
Oran DP, Topol EJ. Prevalence of asymptomatic SARS-CoV-2 infection: a narrative review. Ann Intern Med. 2020;173(5):362–7.
Covid-19: Govt reaches target of testing a million people per day - india news - Hindustan Times. [cited 2020 Dec 28]. Available from: https://www.hindustantimes.com/india-news/govt-reaches-target-of-testing-a-million-people-in-a-day/story-6G33zy5k3VTi5ZF2u7r4bP.html
Agarwal A, Mukherjee A, Kumar G, Chatterjee P, Bhatnagar T, Malhotra P. Convalescent plasma in the management of moderate covid-19 in adults in India: open label phase II multicentre randomised controlled trial (PLACID Trial). BMJ. 2020;371:m3939.
ClinicalManagementProtocolforCOVID19.pdf [Internet]. [cited 2021 Jun 6]. Available from: https://www.mohfw.gov.in/pdf/ClinicalManagementProtocolforCOVID19.pdf
Liu STH, Aberg JA. Convalescent plasma in patients hospitalised with COVID-19. Lancet Lond Engl. 2021;397(10289):2024–5.
COVID_Management_Algorithm_17052021.pdf [Internet]. [cited 2021 Jun 6]. Available from: https://www.icmr.gov.in/pdf/covid/techdoc/COVID_Management_Algorithm_17052021.pdf
Long Q-X, Liu B-Z, Deng H-J, Wu G-C, Deng K, Chen Y-K, et al. Antibody responses to SARS-CoV-2 in patients with COVID-19. Nat Med. 2020;26(6):845–8.
Stringhini S, Wisniak A, Piumatti G, Azman AS, Lauer SA, Baysson H, et al. Seroprevalence of anti-SARS-CoV-2 IgG antibodies in Geneva, Switzerland (SEROCoV-POP): a population-based study. Lancet Lond Engl. 2020;396(10247):313–9.
Max Healthcare Insititute Limited. A Phase II, Open Label, Randomized Controlled Trial to Assess the Safety and Efficacy of Convalescent Plasma to Limit COVID-19 Associated Complications [Internet]. clinicaltrials.gov; 2020 Jul [cited 2020 Dec 23]. Report No.: NCT04374487. Available from: https://clinicaltrials.gov/ct2/show/NCT04374487
Luchsinger LL, Ransegnola BP, Jin DK, Muecksch F, Weisblum Y, Bao W, et al. Serological assays estimate highly variable SARS-CoV-2 neutralizing antibody activity in recovered COVID-19 patients. J Clin Microbiol. 2020;58(12).
GeurtsvanKessel CH, Okba NMA, Igloi Z, Embregts CWE, Laksono BM, Leijten L, et al. Towards the next phase: evaluation of serological assays for diagnostics and exposure assessment. medRxiv. 2020;2020.04.23.20077156.
Behal R, Jain R, Behal KK, Dhole TN. Variation in the host ABO blood group may be associated with susceptibility to hepatitis C virus infection. Epidemiol Infect. 2010;138(8):1096–9.
Onsten TGH, Callegari-Jacques SM, Goldani LZ. The higher frequency of blood group b in a brazilian population with HIV infection. Open AIDS J. 2013;7:47–50.
Guillon P, Clément M, Sébille V, Rivain J-G, Chou C-F, Ruvoën-Clouet N, et al. Inhibition of the interaction between the SARS-CoV spike protein and its cellular receptor by anti-histo-blood group antibodies. Glycobiology. 2008;18(12):1085–93.
Wu Y, Feng Z, Li P, Yu Q. Relationship between ABO blood group distribution and clinical characteristics in patients with COVID-19. Clin Chim Acta Int J Clin Chem. 2020;509:220–3.
Zhao J, Yang Y, Huang H, Li D, Gu D, Lu X, et al. Relationship between the ABO Blood Group and the COVID-19 Susceptibility. Clin Infect Dis Off Publ Infect Dis Soc Am. 2020
Bonelli F, Sarasini A, Zierold C, Calleri M, Bonetti A, Vismara C, et al. Clinical and analytical performance of an automated serological test that identifies S1/S2-neutralizing IgG in COVID-19 patients semiquantitatively. J Clin Microbiol. 2020;58(9):e01224-e1320.
Cheng Y, Wong R, Soo YOY, Wong WS, Lee CK, Ng MHL, et al. Use of convalescent plasma therapy in SARS patients in Hong Kong. Eur J Clin Microbiol Infect Dis Off Publ Eur Soc Clin Microbiol. 2005;24(1):44–6.
Zhou B, Zhong N, Guan Y. Treatment with convalescent plasma for influenza A (H5N1) infection. N Engl J Med. 2007;357(14):1450–1.
Hung IF, To KK, Lee C-K, Lee K-L, Chan K, Yan W-W, et al. Convalescent plasma treatment reduced mortality in patients with severe pandemic influenza A (H1N1) 2009 virus infection. Clin Infect Dis Off Publ Infect Dis Soc Am. 2011;52(4):447–56.
Antibody Detection | National COVID-19 Convalescent Plasma Project [Internet]. [cited 2020 Dec 28]. Available from: https://ccpp19.org/healthcare_providers/virology/antibodies.html
Research C for BE and. Recommendations for Investigational COVID-19 Convalescent Plasma. FDA [Internet]. 2020 [cited 2020 Dec 28]; Available from: https://www.fda.gov/vaccines-blood-biologics/investigational-new-drug-ind-or-device-exemption-ide-process-cber/recommendations-investigational-covid-19-convalescent-plasma
Burgess S, Ponsford MJ, Gill D. Are we underestimating seroprevalence of SARS-CoV-2? BMJ. 2020;370:m3364.
Wu F, Wang A, Liu M, Wang Q, Chen J, Xia S, et al. Neutralizing antibody responses to SARS-CoV-2 in a COVID-19 recovered patient cohort and their implications. medRxiv. 2020;2020.03.30.20047365.
Wu F, Liu M, Wang A, Lu L, Wang Q, Gu C, et al. Evaluating the association of clinical characteristics with neutralizing antibody levels in patients who have recovered from mild COVID-19 in Shanghai, China. JAMA Intern Med. 2020;180(10):1356–62.
Studies offer new evidence for possible link between blood type and COVID-19 susceptibility: Individuals with blood type O may have lowest risk of infection; individuals with A and AB may have increased risk of severe clinical outcomes [Internet]. ScienceDaily. [cited 2020 Dec 28]. Available from: https://www.sciencedaily.com/releases/2020/10/201014161544.htm
Garcia-Basteiro AL, Moncunill G, Tortajada M, Vidal M, Guinovart C, Jiménez A, et al. Seroprevalence of antibodies against SARS-CoV-2 among health care workers in a large Spanish reference hospital. Nat Commun [Internet]. 2020 [cited 2020 Dec 28];11. Available from: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7343863/
Liu J, Liu Y, Xiang P, Pu L, Xiong H, Li C, et al. Neutrophil-to-lymphocyte ratio predicts critical illness patients with 2019 coronavirus disease in the early stage. J Transl Med. 2020;18(1):206.
Zhang B, Zhou X, Zhu C, Song Y, Feng F, Qiu Y, et al. Immune Phenotyping Based on the neutrophil-to-lymphocyte ratio and IgG level predicts disease severity and outcome for patients with COVID-19. Front Mol Biosci [Internet]. 2020 [cited 2020 Dec 28];7. Available from: https://www.frontiersin.org/articles. Doi: https://doi.org/10.3389/fmolb.2020.00157/full#B6
Peiris JSM, Chu CM, Cheng VCC, Chan KS, Hung IFN, Poon LLM, et al. Clinical progression and viral load in a community outbreak of coronavirus-associated SARS pneumonia: a prospective study. Lancet Lond Engl. 2003;361(9371):1767–72.
Hong K-H, Choi J-P, Hong S-H, Lee J, Kwon J-S, Kim S-M, et al. Predictors of mortality in Middle East respiratory syndrome (MERS). Thorax. 2018;73(3):286–9.
Yang HS, Costa V, Racine-Brzostek SE, Acker KP, Yee J, Chen Z, et al. Association of age with SARS-CoV-2 antibody response. JAMA Netw Open. 2021;4(3):e214302.
Bajaj V, Gadi N, Spihlman AP, Wu SC, Choi CH, Moulton VR. Aging, immunity, and COVID-19: How age influences the host immune response to coronavirus infections? Front Physiol. 2020;11:571416.
Hou H, Wang T, Zhang B, Luo Y, Mao L, Wang F, et al. Detection of IgM and IgG antibodies in patients with coronavirus disease 2019. Clin Transl Immunol. 2020;9(5):e01136.
Use of convalescent plasma for COVID-19 in India: A review & practical guidelines. 2021 [cited 2021 Feb 16]; Available from: https://www.ijmr.org.in/preprintarticle.asp?id=308620;type=0